Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial)

Abstract

This study aimed to determine the effects of polyethylene glycol loxenatide (PEG-Loxe), a glucagon-like peptide-1 receptor agonist, on a three-point major adverse cardiovascular event (3P-MACE) in patients with type 2 diabetes mellitus (T2DM). The study was conducted in six tertiary hospitals in three cities in China. Large language models were used to retrospectively screen and include 12,341 patients with T2DM who had either cardiovascular disease or cardiovascular risk factors. The patients were divided into the PEG-Loxe cohort (treated with PEG-Loxe, n = 1282) and the control cohort (treated with incretin glucose-lowering agents, n = 11,059). After a median follow-up of 4.0 years, 3P-MACE occurred in 51 (4.0%) and 1263 (11.4%) patients in PEG-Loxe and control cohorts, respectively (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.49–0.94; p = 0.019). In the PEG-Loxe versus control cohorts, 21 (1.6%) versus 476 (4.3%) patients experienced nonfatal stroke (HR 0.63; p = 0.041), whereas 22 (1.7%) versus 545 (4.9%) experienced nonfatal myocardial infarction (HR 0.66; p = 0.058), and the incidence of cardiovascular death was 8 (0.6%) versus 240 (2.2%), respectively (HR 0.56; p = 0.118). We found a significantly lower incidence of first nonfatal myocardial infarction, nonfatal stroke, or cardiovascular deaths in the PEG-Loxe cohort than the control cohort.

Keywords

ambispective cohort study / cardiovascular / glucagon-like peptide-1 receptor agonist / myocardial infarction / polyethylene glycol loxenatide / type 2 diabetes

References

[1] Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021; 183: 109119.

[2] Mouri M, Badireddy M. Hyperglycemia. In StatPearls. StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK430900/

[3] Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018; 14(6): 491-509.

[4] Nelson AJ, Pagidipati NJ, Aroda VR, et al. Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation. 2021; 144(1): 74-84.

[5] Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021; 1307: 171-192.

[6] Mariam Z, Niazi SK. Glucagon-like peptide agonists: a prospective review. Endocrinol Diabetes Metab. 2024; 7(1): e462.

[7] Honigberg MC, Chang LS, McGuire DK, et al. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiol. 2020; 5(10): 1182-1190.

[8] Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834-1844.

[9] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311-322.

[10] Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193): 121-130.

[11] Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021; 385(10): 896-907.

[12] Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157): 1519-1529.

[13] Rafehi M, Moller M, Ismail Al-Khalil W, et al. Medicinal polypharmacology in the clinic – translating the polypharmacolome into therapeutic benefit. Pharm Res. 2024; 41(3): 411–417.

[14] Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024; 267: 1-11.

[15] Chen X, Lv X, Yang G, et al. Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients. J Diabetes. 2017; 9(2): 158-167.

[16] Yang GR, Zhao XL, Jin F, et al. Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes. J Clin Pharmacol. 2015; 55(2): 152-158.

[17] Gao F, Lv X, Mo Z, et al. Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 3b trial. Diabetes Obes Metab. 2020; 22(12): 2375-2383.

[18] Shuai Y, Yang G, Zhang Q, et al. Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: a multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial. Diabetes Obes Metab. 2021; 23(1): 116-124.

[19] Cai H, Chen Q, Duan Y, et al. Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: an open-label, parallel-arm, randomized, metformin-controlled trial. Front Endocrinol (Lausanne). 2023; 14: 1106868.

[20] Cao Y, Cao S, Zhao J, et al. Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial. Front Endocrinol (Lausanne). 2024; 15: 1387993.

[21] Yuan J, Wang Y, Wang D, et al. Loxenatide attenuates ROS-mediated vascular endothelial progenitor cell damage and mitochondrial dysfunction via SIRT3/Foxo3 signaling pathway. J Biochem Mol Toxicol. 2023; 37(11): e23452.

[22] Chen F, He L, Li J, et al. Polyethylene glycol loxenatide injection (GLP-1) protects vascular endothelial cell function in middle-aged and elderly patients with type 2 diabetes by regulating gut microbiota. Front Mol Biosci. 2022; 9: 879294.

[23] Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022; 102(5S): S1-S127.

[24] ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023; 46(Suppl 1): S140-S157.

[25] Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999; 319(7223): 1492-1495.

[26] Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373(23): 2247-2257.

[27] Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228-1239.

[28] Pan Q, Yuan M, Guo L. Exposure-response analysis of cardiovascular outcome trials with incretin-based therapies. Front Endocrinol (Lausanne). 2022; 13: 893971.

[29] Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid. 2011; 6: 67-79.

[30] Murphy CE. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2012; 46(6): 812-821.

[31] Ingwersen SH, Petri KC, Tandon N, et al. Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with type 2 diabetes from China, India and South Korea. Diabetes Res Clin Pract. 2015; 108(1): 113-119.

[32] Carlsson Petri KC, Ingwersen SH, Flint A, et al. Semaglutide s.c. Once-weekly in type 2 diabetes: a population pharmacokinetic analysis. Diabetes Ther. 2018; 9(4): 1533-1547.

[33] Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016; 55(5): 625-634.

[34] Lim CY, In J. Randomization in clinical studies. Korean J Anesthesiol. 2019; 72(3): 221-232.

[35] Guevara M, Chen S, Thomas S, et al. Large language models to identify social determinants of health in electronic health records. NPJ Digit Med. 2024; 7(1): 6.

[36] Lebwohl M, Koo J, Leonardi C, et al. Brodalumab: 4-year US pharmacovigilance report. J Drugs Dermatol. 2023; 22(4): 419-422.

[37] Xie Y, Kuang J, Li Q, et al. Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3). BMJ Open. 2023; 13(5): e069080.

[38] Du Z, Wang Y, Bai Y, et al. Estimate of COVID-19 deaths, China, December 2022-February 2023. Emerg Infect Dis. 2023; 29(10): 2121-2124.

[39] Vosko I, Zirlik A, Bugger H. Impact of COVID-19 on cardiovascular disease. Viruses. 2023; 15(2): 508.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.